US
Cancer drugs have surged since the 80s to account for 1 in 4 FDA approvals, report reveals
September 5, 2019Research and Development, Sales and Marketing Cancer, FDA, US, pharma
The number of cancer drug approvals in the US has surged over the last decade to account for over one …
Alexion’s Soliris scoops up expanded EU approval in neuromyelitis optica spectrum disorder
August 28, 2019Research and Development, Sales and Marketing Alexion, FDA, US, pharma, soliris
Alexion has announced the expanded EU approval of Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in …
FDA greenlights Nebriva’s Xenleta for community-acquired bacterial pneumonia
August 20, 2019Manufacturing and Production, Sales and Marketing FDA, Nabriva, US, Xenleta, pharma, pneumonia
The FDA has awarded approval in the US to Nebriva Therapeutics’ Xenleta (lefamulin) for the treatment of adult patients with …
British and American healthcare professionals predict further delays to Brexit as Europeans expect no-deal
August 19, 2019Sales and Marketing EU, UK, US, brexit, brexit delay, healthcare, no-deal, pharma
The majority of healthcare professionals in Europe, Britain and America think Brexit will happen. However they do not believe that …
FDA approve new drug for treatment-resistant TB
August 15, 2019Research and Development FDA, TB, US, pharma, pretomanid, tuberculosis
The US FDA has approved BPaL, the TB Alliance’s treatment for drug-resistant tuberculosis (TB). The US regulator gave the go-ahead …
Brammer Bio to set up new plant in Norton, Massachusetts
August 12, 2019Sales and Marketing Brammer Bio, Massachusetts, US, norton, pharma
Cambridge, Massachusetts-based Brammer Bio is planning to set up a new manufacturing facility in Norton, Massachusetts. The Thermo Fisher subsidiary …
Daiichi Sankyo’s Turalio becomes first FDA-approved therapy for rare tumour
August 5, 2019Sales and Marketing Cancer, Daiichi Sankyo, FDA, Turalio, US, pharma, rare cancer
Daiichi Sankyo has seen its CSF1R inhibitor Turalio (pexidartinib) approved by the FDA in the treatment of symptomatic tenosynovial giant …
US presidential candidate Bernie Sanders pledges to allow Americans to import drugs from Canada
August 2, 2019Medical Communications Bernie Sanders, Canada, Trump, US, democrats, prescription drugs
Democratic presidential candidate Bernie Sanders has said he will, on his first day in office, allow for the importation of …
MSD to bring over 400 new jobs to North Carolina with two site expansions
July 31, 2019Manufacturing and Production, Research and Development MSD, US, pharma
MSD has announced a $650 million expansion of its existing facilities in North Carolina – a move which is bring …
Top Ten most popular articles on Pharmafile.com this week
July 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biohaven, FDA, Lyrica, NICE, Pfizer, UK, US, pharma, top ten
At the end of a week that could certainly be called “eventful” here in the UK – one that saw …
Lilly’s Baqsimi nasal powder gains FDA approval after proving non-inferior to injection
July 25, 2019Sales and Marketing Baqsimi, Eli Lilly, FDA, US, diabetes, pharma
Eli Lilly has been awarded approval from the FDA for its Baqsimi nasal powder in the treatment of severe hypoglycaemia, …
Ohio prosecutors file charges against opioid distributor Miami-Luken
July 22, 2019Sales and Marketing US, USA, West Virginia, criminal case, opioid crisis, opioids
Federal prosecutors in Cincinnati have filed criminal charges against opioid distributor Miami-Luken, and four others, over the role they played …
FDA approves MSD’s combo therapy Recarbrio for urinary tract and intra-abdominal infections
July 18, 2019Sales and Marketing FDA, MSD, Recarbrio, US, pharma, urinary tract
MSD has announced the approval from the FDA of its combination therapy Recarbrio (imipenem, cilastatin and relebactam) in the treatment …
AstraZeneca’s Farxiga fails to get FDA approval for patients with Type 1 diabetes
July 15, 2019Sales and Marketing AstraZeneca, EMA, FDA, US, diabetes, farxiga
The FDA had said it will not approve AstraZeneca’s diabetes drug Farxiga for use as a supplement to insulin in …
Novartis aims to solve EpiPen shortage with generic launch of Symjepi to US pharmacies
July 10, 2019Manufacturing and Production, Research and Development, Sales and Marketing Mylan, Novartis, Sandoz, US, epipen, pharma
Novartis has announced the immediate availability of its generic epinephrine auto-injector in pharmacies throughout the US, as it moves to …
Latest content
FibroFind appoints Lee Borthwick as CEO
